{
  "docId": "019de072-47f9-754b-bd81-b37e2d3aff4a",
  "docSlug": "3579f0f2aa567a18deef7848f39c9b29",
  "documentTitle": "argenx SE | Results Presentation Deck | 17 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 3,
  "pageCount": 17,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "thesis_headline",
  "function": "establish_context",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "Includes mandatory regulatory disclosure link at the bottom.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-47f9-754b-bd81-b37e2d3aff4a/3",
  "deckHref": "/decks/019de072-47f9-754b-bd81-b37e2d3aff4a",
  "deckJsonHref": "/decks/019de072-47f9-754b-bd81-b37e2d3aff4a.json",
  "deckAnchorHref": "/decks/019de072-47f9-754b-bd81-b37e2d3aff4a#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.022,
        "w": 0.67,
        "x": 0.165,
        "y": 0.938
      },
      "kind": "disclaimer",
      "text": "Please see Important Safety Information and the full Prescribing Information for VYVGART at https://vyvgart.com",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a8015105-ee36-497e-b0ad-cdc9f0db19b4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.176,
        "w": 0.508,
        "x": 0.246,
        "y": 0.318
      },
      "kind": "image",
      "text": "VYVGART (efgartigimod alfa-fcab)",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "283791d7-2869-4a3a-af9e-49bf67863655",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.088,
        "w": 0.782,
        "x": 0.109,
        "y": 0.714
      },
      "kind": "paragraph",
      "text": "VYVGART is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) antibody positive",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0183126c-6c5c-4622-95b9-ccfe7ec5ef8d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.116,
        "w": 0.632,
        "x": 0.336,
        "y": 0.064
      },
      "kind": "title",
      "text": "VYVGART IS NOW FDA-APPROVED",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6e976158-ca0e-408a-b7d9-328e9c4802d0",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 4,
      "from": 3,
      "beatId": "c551e8a4-ba9b-455c-a097-cea4c784831a",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Problem (Identify pain)",
      "beatSlug": "problem-agitate-solution-problem-identify-pain",
      "evidence": "The presentation identifies the limitations of current gMG treatments and the need for new solutions.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 6,
      "from": 3,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "8074f39d-c5c8-49a7-b1a2-34670dd56fb4",
      "evidence": "The presentation implies that not adopting VYVGART would mean missing out on a potentially life-changing treatment option.",
      "position": 0,
      "objective": "What are the consequences of not adopting VYVGART?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}